Truist Maintains Buy Rating on Ovintiv, Raises Target to $77
Truist Securities maintained its Buy rating on Ovintiv and raised its price target to $77 per share from $73.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.